Merck looks to cardiovascular pipeline for $10B+ peak sales—and diversification from Keytruda

Under pressure to diversify from the blockbuster cancer med Keytruda, Merck & Co. is looking to its cardiovascular portfolio in hopes of finding $10 billion in peak revenue by the mid-2030s—depending on the approval of eight potential therapies.